Form 4: BioCryst Pharmaceuticals Director Equity Grants

Amy E. McKee, a Director at BioCryst Pharmaceuticals, received grants of Restricted Stock Units and stock options.

Summary

• Amy E. McKee, a Director at BioCryst Pharmaceuticals Inc. (BCRX), was granted 15,294 shares of Common Stock on June 11, 2026, with a reported value of $0, bringing her total beneficial ownership to 47,177 shares.
• Additionally, McKee received an automatic grant of 33,540 stock options with an exercise price of $8.50 on June 11, 2026. These options are exercisable starting June 11, 2027, and expire on June 11, 2036.
• The Restricted Stock Units (RSUs) granted will vest on the first anniversary of the grant date.
• These transactions were made under the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine equity grants to a director under an established compensation policy, with no immediate financial performance indicators or significant strategic shifts disclosed.

Positives

• Director Amy E. McKee received equity grants, indicating continued alignment with shareholder interests.
• The grant of stock options with an exercise price of $8.50 suggests a potential for future value creation if the stock price appreciates.
• The vesting schedule for RSUs on the first anniversary encourages long-term commitment.

Negatives

• The reported value of the 15,294 shares of Common Stock acquired was $0, which may require further clarification regarding the accounting treatment or grant conditions.
• The filing does not provide current market price or valuation details for the granted securities.

Risks

• The value of the stock options is contingent on the future performance of BioCryst Pharmaceuticals' stock price.
• Vesting of RSUs and exercisability of options are subject to continued service as a director.

Future Outlook

The future outlook for the granted equity is dependent on the company's stock performance and the director's continued service. The stock options provide a potential upside if the stock price exceeds $8.50.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the pharmaceutical industry to incentivize leadership and align their interests with those of shareholders, particularly in companies focused on drug development where long-term strategic vision is crucial.

Stakeholder Impact

• Shareholders: The equity grants to directors align management incentives with shareholder value creation, assuming the stock price increases.
• Employees: The compensation policy for directors may set a precedent or standard for other equity-based compensation within the company.
• Management: Directors are incentivized to perform and contribute to the company's success to realize the value of their equity grants.

Next Steps

• Vesting of Restricted Stock Units on the first anniversary of the grant date.
• Exercisability of stock options beginning on June 11, 2027.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, SEC Filing